September 2, 2017

Consultation opened on the new EMA’s concept paper on development and lifecycle of personalised medicines and companion diagnostics

The EMA has released for public consultation a concept paper on the development and lifecycle of personalised medicines and companion diagnostics. The concept paper is intended to be developed into a guideline which will replace the existing reflection paper on co-development of pharmacogenomics markers and assays in the context of drug development dated 24 June 2010.

For the purpose of the concept paper, the term “personalised medicine” refers to the targeted use of a treatment in a patient on the basis of the individual’s characteristics and genetic makeup and the understanding of how the treatment works. To that end, it is necessary to measure the predictive biomarkers (BM) and this is made by means of a device called companion diagnostic (CDx). CDx is defined for the first time in the new in vitro diagnostic medical devices regulation (IVDR) as “a device which is essential for the safe and effective use of a corresponding medicinal product to: (i) identify, before and/or during treatment, patients who are most likely to benefit from the corresponding medicinal product; or (ii) identify, before and/or during treatment, patients likely to be at increased risk for serious adverse reactions as a result of treatment with the corresponding medicinal product”.

If it is recommended in the labelling that a medicinal product should be used in conjunction with a predictive BM, any commercial assay used for this purpose will be considered a CDx and will require an appropriate conformity certificate (CE mark).

In Europe, the legislations covering the marketing of medicinal products and IVD medical devices are not directly linked. The new IVDR envisages cooperation between notified bodies and medicines regulators in the evaluation of new CDx for obtaining a CE mark, although this will not lead to approval by medicines regulators of one or more specific CDx for use in conjunction with a given drug.

The fact that developments of medicinal products and IVDs are often independent, coming together only superficially towards the end causes gaps in evidence and validations. The proposed guideline intends to help to optimise the co-development of medicinal products and companion diagnostics, including their combined use in clinical trials to generate evidence required to support validation of the diagnostic.

Comments on the concept paper may be submitted by 15 November 2017. Then, the process will continue with the issuance of a draft guideline, that will be available 9-12 months after the end of the public consultation of the concept paper and will be released for 6 months external consultation.

< Back to blog
Welcome to the Portolano Cavallo Life Sciences blog focusing on legal development and key legal issues affecting the life sciences and healthcare industry.
...
Read more
Our highly-ranked team of professionals will provide newsinsights and multidisciplinary commentary on the hottest and most recent regulatory, transactional and contentious aspects of the pharmaceutical, bio-tech, med-tech, food supplement and healthcare world with an eye on its digital transformation and technological developments.

This blog will be a place for focusing on digital health, telemedicine and artificial intelligence, as well as more traditional topics: from the protection of intellectual properties to performance of clinical trials, from the market access to advertising and competition issues, from internal and criminal investigations to M&A and venture capital transactions.

Close
June 6, 2022
The National Coordination Centre for Ethics Committees published new draft agreements for conducting clinical trials on drugs and medical devices
April 27, 2022
EU Medical Device Coordination Group (MDCG) approves “Guidance” on the borderline between medical devices and medicinal products in order to support the uniform application of Regulation...
April 5, 2022
Electronic prescriptions: the current modalities of transmission from doctors to patients and from patients to pharmacies are extended until 31st December 2022
March 24, 2022
EU Medical Device Coordination Group (MDCG) approves “Guidance” on appropriate surveillance of devices covered by certificates according to the MD Directives, under the transitional prov...
March 21, 2022
Published Decree of Health Ministry identifying the ethics committees of national significance for clinical trials of medicinal products and medical devices
Search by...
Search
Follow us on
Follow us on